Pet IL-13 Therapeutic Antibody Development

Creative Biolabs provides advanced solutions for the discovery and development of therapeutic antibodies targeting cytokines that drive chronic disease in companion animals. Our IL-13 therapeutic antibody programs are designed to address unmet medical needs in canine and feline health, combining innovative discovery platforms with comprehensive development services. With an integrated approach and deep expertise in veterinary immunology, we help research teams translate novel concepts into viable therapies that improve the lives of pets. If your organization is exploring IL-13 as a therapeutic target, we invite you to engage with us to shape a custom development strategy.

Platforms in Therapeutic Antibody Discovery

We provide multiple discovery platforms, which operate independently or be combined to maximize discovery success. For inquiries about which strategy best aligns with your IL-13 antibody program, our team can provide tailored recommendations.

• Phage Display: We employ canine and feline phage display libraries tailored for veterinary use. This enables efficient screening of vast antibody repertoires against IL-13, providing high-affinity candidates suitable for downstream optimization.
• Single-B Cell Sorting: Our single-B cell sorting capabilities allow rapid identification of murine antibody leads, which can then be engineered and adapted for canine or feline therapeutic use. This platform captures natural antibody diversity and accelerates translation into optimized biologics.
• Hybridoma Technology: Hybridoma-based discovery remains a powerful and stable method for generating monoclonal antibodies. We leverage this platform to create IL-13-specific antibodies that serve as strong foundations for engineering and therapeutic development.

Comprehensive Antibody Development Services

Our integrated service model ensures that antibody programs progress efficiently, with minimal risk of delays. Connect with Creative Biolabs to learn how our workflows can streamline your IL-13 therapeutic development.

Antibody Characterization

In-depth evaluation of binding strength, stability, specificity, and functional inhibition of IL-13 signaling.

Antibody Engineering

Optimization of candidate molecules for veterinary applications, including reducing immunogenicity and improving pharmacological profiles.

Preclinical Evaluation

Comprehensive safety and efficacy testing in relevant in vitro models and animal models to ensure readiness for translational research.

Antibody Development

Scalable production processes designed to maintain consistency, quality, and efficiency across preclinical and clinical phases.

Discover How We Can Help - Request a Consultation

Why Focus on IL-13?

IL-13 is a type 2 cytokine known for its role in allergic and inflammatory responses. In dogs, IL-13 is a major driver of atopic dermatitis, contributing to pruritus, skin barrier dysfunction, and chronic inflammation. In cats, IL-13 has been implicated in respiratory conditions resembling asthma, where it promotes mucus hypersecretion and airway hyperresponsiveness. Both species may also experience IL-13-related gastrointestinal inflammation, making it a cross-species therapeutic target of significant importance. Targeting IL-13 allows for the development of biologics that directly address the immunological pathways underlying chronic allergic and inflammatory disease in companion animals.

Mechanism of Action

Therapeutic antibodies targeting IL-13 function by neutralizing the cytokine, preventing it from binding to its receptor complex (IL-13Rα1/IL-4Rα). This interruption halts downstream signaling pathways, such as STAT6 activation, which drive inflammation, mucus production, and tissue remodeling. By inhibiting IL-13 activity, these antibodies restore immune balance, reduce pathological inflammation, and alleviate disease symptoms. In pets, this mechanism provides a more precise and effective treatment approach compared to broad-spectrum immunosuppressive drugs.

Fig 1. Canine IL13RA2 and EPHA2 testings in the trial.¹

Our Advantages

• Veterinary-Centered Expertise: Specialized focus on canine and feline immunology ensures relevance and therapeutic translation.
• Integrated Capabilities: From discovery to preclinical evaluation, we provide seamless workflows under one roof.
• Customizable Solutions: Flexible project design to meet unique client goals and development timelines.
• Commitment to Quality: High analytical standards and robust QC pipelines guarantee reliable outcomes.

Partner with Creative Biolabs

IL-13 remains a pivotal cytokine in chronic allergic and inflammatory diseases of dogs and cats. Antibody therapies against this target hold promise for transforming treatment strategies and improving quality of life in companion animals. Creative Biolabs brings together advanced discovery platforms, comprehensive development services, and species-specific expertise to deliver impactful results.

We invite you to reach out and discuss your IL-13 antibody project with our team. Together, we can design a pathway from concept to therapy, ensuring your innovation reaches the pets who need it most. Contact Creative Biolabs today to begin your IL-13 therapeutic antibody development journey.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Rossmeisl, John H., et al. "Phase I trial of convection-enhanced delivery of IL13RA2 and EPHA2 receptor targeted cytotoxins in dogs with spontaneous intracranial gliomas." Neuro-oncology 23.3 (2021): 422-434. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1093/neuonc/noaa196